Short Interest in InflaRx (NASDAQ:IFRX) Expands By 15.0%

InflaRx (NASDAQ:IFRX - Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 248,900 shares, a growth of 15.0% from the December 31st total of 216,500 shares. Based on an average daily volume of 264,900 shares, the short-interest ratio is currently 0.9 days.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and issued a $8.00 price objective on shares of InflaRx in a research note on Thursday, January 16th.

InflaRx Price Performance

InflaRx stock traded up $0.06 during mid-day trading on Tuesday, hitting $2.47. 296,082 shares of the company's stock traded hands, compared to its average volume of 201,104. The firm has a 50 day simple moving average of $2.41 and a two-hundred day simple moving average of $1.86. InflaRx has a fifty-two week low of $1.16 and a fifty-two week high of $2.82. The stock has a market cap of $145.43 million, a price-to-earnings ratio of -2.29 and a beta of 1.63.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its earnings results on Friday, November 8th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.06). InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%. The company had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.05 million. During the same quarter in the prior year, the business posted ($0.14) EPS. On average, research analysts anticipate that InflaRx will post -1.04 earnings per share for the current fiscal year.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.